The present study aimed to assess the inter-observer concordance in the reporting of HER2-low and ultralow breast carcinoma among expert breast pathologists to assess the accuracy of identifying this group of tumours, highlight areas of reporting difficulty and provide suggestions for improving analytical consistency. This evidence concerns the gene ERBB2 and breast carcinoma.